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Overgrowth syndromes comprise a heterogeneous group of diseases that are characterized by excessive tissue development. Some
of these syndromes may be associated with dysfunction in the receptor tyrosine kinase (RTK)/PI3K/AKT pathway, which results
in an increased expression of the insulin receptor. In the current review, four overgrowth syndromes were characterized (Proteus
syndrome,Klippel-Trenaunay-Webersyndrome,Madelung’sdisease,andneurofibromatosistypeI)andillustratedusingcasesfrom
our institution. Because these syndromes have overlapping clinical manifestations and have no established genetic tests for their
diagnosis,radiologicalmethodsareimportantcontributorstothediagnosisofmanyofthesesyndromes.Thecorrelationofgenetic
discoveriesandmolecularpathwaysthatmaycontributetothephenotypicexpressionisalsoofinterest,asthismayleadtopotential
therapeutic interventions.
1. Introduction
Longitudinal growth results from multifactorial and com-
plex processes that take place in the broader context of
different genetic traits and environmental influences [1, 2].
Overgrowth syndromes comprise a heterogeneous group of
disorders that lead to excessive tissue proliferation, which is
c h a r a c t e r i z e db yap h e n o t y p eo fe x c e s s i v es o m a t i ca n dv i s -
ceral growth [1–3]. A myriad of syndromes are characterized
by substantial localized or asymmetric tissue overgrowth,
represented by Beckwith-Wiedemann syndrome, Sotos syn-
drome, Proteus syndrome, Klippel-Trenaunay-Weber syn-
drome,Madelung’sdisease,neurofibromatosistypeI,Weaver
syndrome, Nevo syndrome, Simpson-Golabi-Behmel syn-
drome, Bannayan-Riley-Ruvalcaba syndrome, Perlman syn-
drome, Pallister-Killian syndrome, and many other condi-
tions. The Beckwith-Wiedemann and Sotos syndromes are
t h em o s tf r e q u e n t[ 1–4]. Overgrowth syndromes can be
l o c a l i z e do rd i ff u s ea n do ft e nm a n i f e s ta tb i r t ho ri nt h e
postnatal period [4].
Th o u g hm o s tg r o w t hs y n d r o m eh a v eag e n e t i cb a s i s ,
others such as Madelung’s disease have unknown etiology
[4].Geneticassociationsarealreadywellestablishedforsome
conditions including Weaver, Perlman, and Proteus syn-
dromes[2].ThefactthatMadelung’sdiseasetendstooccurin
older males and is often associated with heavy alcohol con-
sumption in 60–90% of cases suggests that it is an acquired
abnormality or more susceptible to environmental modifiers
[5,6].Importantly,mostofthesesyndromesleadtoincreased
risks of cognitive disorders and cancers [7]. The frequency
of cancer is well documented in some syndromes such as
Proteus (20%), Sotos (2–4%), and Perlman (65%) [2]. In
some overgrowth syndromes, such as Beckwith-Wiedemann
and Perlman syndromes, tumors appeared mostly in the
abdomen; conversely, in other overgrowth syndromes, such
as Sotos syndrome, the most frequent type of overgrowths is
extra-abdominally located lymphohematological tumors [8].
A dysfunction in the receptor tyrosine kinase (RTK)/
PI3K/AKT pathway that specifically promotes a rapid
increase in insulin receptor expression is most likely the
pathophysiological basis of some overgrowth syndromes [4].
Insulin receptor stimulation leads to an increase in PI3-
kinase activity, which thereby generates PIP3 and leads to
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the activation of PKB/Akt [4]. This pathway plays an impor-
tant role in the activation of somatic mutations in various
tumors as well as in apoptosis, angiogenesis, and brain
development [9–11]. A dysfunction in the (RTK)/PI3K/AKT
pathway has been described in some conditions such as
Proteus syndrome [4]. The genetic factor is intrinsically
involved in some overgrowth syndromes. It is noteworthy to
highlight the imprinted growth regulatory genes on chromo-
some11p15.5.In thisregion,thereisonedomaininwhichthe
H19 expression from the maternal allele is thought to protect
against the tall stature. There is also a second domain that
consists of the CDKN1C gene, which acts as an in-utero neg-
ative regulator of cell growth. Heritable forms of Beckwith-
W i e d e m a n ns y n d r o m eh a v eb e e na t t r i b u t e dm a i n l yt om u t a -
tions in the growth suppressor gene CDKN1C [2, 12]. There
are some reports of NSD-1 mutations in individuals with
Sotos and Weaver syndromes and more recently muta-
tions in the EZH2 gene in three families with Weaver
syndrome have been identified [13]. A previously unknown
susceptibility locus was mapped and germline mutations in
DIS3L2 i d e n t i fi e di ni n d i v i d u a l sw i t hP e r l m a ns y n d r o m e .
Functional studies demonstrated that underexpression of the
DIS3L2 gene was associated with cellular growth enhance-
ment [14].
Several classifications have been developed in an attempt
to facilitate the diagnosis of these syndromes, but these
attempts have been hindered by the syndromes’ several
overlapping clinical manifestations [1, 15]. Neylon et al.
[2] proposed a classification of overgrowth syndromes by
ordering them according to their typical timing of clinical
presentationasfollows:(a)syndromesexhibitingovergrowth
in the neonatal period, including Beckwith-Wiedemann syn-
drome, Sotos syndrome, Weaver syndrome, and Perlman
syndrome and (b) overgrowth syndromes usually identified
in childhood, including Klinefelter syndrome and Proteus
syndrome. Major progress such as the identification of
genetic causes has recently enhanced the knowledge of the
underlying pathophysiological mechanisms, the delineation
of the genotype-phenotype relationships, and the establish-
ment of the main characteristics for each condition [1]. As a
consequence,thepossibilitiesfordistinguishingbetweendif-
ferent overgrowth syndromes have increased. Several studies
are currently underway to organize these types of disorders
accordingtoamolecularclassificationsystemforovergrowth
syndromes in order to assist the practicing clinician [16–
18].Radiologicalabnormalitiesareincreasinglyimportantfor
the clinical differentiation between overgrowth syndromes,
making those abnormalities valuable diagnostic criteria for
some of these conditions.
In this review, four overgrowth syndromes—Proteus
syndrome, Klippel-Trenaunay-Weber syndrome, Madelung’s
disease, and neurofibromatosis type I—are described. The
main clinical and imaging features these syndromes are
highlighted using clinical cases evaluated in our institution.
Although they are not the most common overgrowth syn-
dromes,manifestationsofthesefoursyndromesoverlapwith
other more prevalent overgrowth syndromes. Thus, it is of
interesttopresentthesecaseswhichwerediagnosedfromthe
suspicion caused by imaging findings.
Figure 1: The right costovertebral joint space is fused. The T12
vertebra shows disproportionate asymmetric overgrowth which is
characteristic for the Proteus syndrome.
2. Proteus Syndrome
Proteus syndrome is a congenital disorder of unknown
etiology, and it is the prototype of overgrowth syndromes.
It was first described in 1979 and is characterized by multi-
systeminvolvementandclinicalvariability[19].Thisdisorder
became prominent in 1980 after being depicted in the movie
The Elephant Man [19, 20]. Proteus syndrome is a rare
condition with an estimated prevalence of one in 1 million
people worldwide [21]. A study showed a somatic activating
mutation of the AKT1 o n c o g e n ek i n a s e ,a ne n z y m ei n v o l v e d
incellproliferation,inthisdisorder[22].Thisfindingimplies
the activation of the PI3K-AKT pathway in the characteristic
clinical findings of overgrowth and tumor susceptibility in
patients with Proteus syndrome [22].
Proteus syndrome can affect all three germ lineages.
Abnormal asymmetric growth and hemihypertrophy are its
typicalclinicalmanifestations,thoughovergrowthofthelong
bones, macrodactyly, asymmetric macrocephaly, plantar or
palmar hyperplasia, vertebral abnormalities, lipoma, heman-
gioma, connective tissue nevi, lymphangiomas, and vascular
malformations can also be observed in this syndrome [7, 23–
25]. Because there is no specific genetic testing, the diagnosis
of this syndrome is based on clinical data and radiological
evolutions according to the criteria formulated in 1998 by the
National Institutes of Health [19, 23]. The primary hallmark
of Proteus syndrome is a mosaic or random distribution of
lesions throughout the body that develop gradually during
childhood, after which point the disease can stabilize or
continue to slowly progress [23]. Some authors believe that
thediseasebecomesstableatapproximately15–17yearsofage
[21, 26].
Skeletal changes are the most frequently expressed man-
ifestations of Proteus syndrome and include kyphoscol-
iosis, macrodactyly, hyperostosis, asymmetric overgrowth
of limbs, abnormal vertebral bodies (Figure 1), craniofa-
cial abnormalities, and focal calvarial thickening [19, 23,
25]. Among the soft tissue manifestations, asymmetric
growth of the subcutaneous tissue (Figure 2)i sc o m m o n
andmaybeassociatedwithexacerbatedmuscledevelopment
and the proliferation of lymphatic channels and vascular
malformations [19, 23]. Connective tissue nevi may alsoRadiology Research and Practice 3
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Figure 2: A 21-year-old man with Proteus syndrome presenting asymmetric lower limbs and epidermal nevus. CT of the abdomen showed
tissue with a fat density infiltrating the right paraspinal musculature, with increased local volume extending from T7 to L5, in addition to an
enlargement of the right kidney (a). The scan also noted fatty replacement in right gluteal muscles (b). Coronal CT showed asymmetry of the
kidneys (c).
be observed, particularly in the plantar region, as well as
cerebriform nevi [23]. Cerebral arteriovenous malforma-
tions,abnormalgrey-whitematterdifferentiation,andhydro-
cephalusarealsocommonfindings.Visceralchanges,suchas
splenomegaly or nephromegaly (Figure 2), hydronephrosis,
pancreatic lipomas, colonic polyps, emphysema, and lung
cysts are less common findings [19, 23, 24]. All of these con-
ditions aid in the differential diagnosis of Proteus Syndrome,
which can be challenging because Klippel-Trenaunay-Weber
syndrome, Maffucci’s syndrome, enchondromatosis, neurofi-
bromatosis type I, Bannayan-Zonana syndrome, hemihyper-
plasia,andMadelung’sdiseasecanalsocauseovergrowth[24,
27]. Importantly, disproportionate asymmetric overgrowth
can be a clue to the differential diagnosis of other diseases of
osseous overgrowth in which the enlarged bones retain their
normal proportional relationships [24–26].
3. Klippel-Trenaunay-Weber Syndrome
Klippel-Trenaunay-Webersyndromeisrareandhasanuncer-
tain origin with an incidence of approximately 1:100,000 live
births [28]. It appears to have no predilection for gender or
race, and most of the cases are sporadic and appear at birth
[29, 30]. The French physicians Maurice Klippel and Paul
Trenaunay first described this syndrome in 1900 when they
associated vascular malformations with hypertrophy in the
affected limb. Subsequently, arteriovenous fistulas in these
patients were described by Parkes Weber [30–32]. Several
theories attempt to elucidate the etiology of this syndrome,
such as multifactorial, paradominant inheritance, or mosaic
mutation[33].Someauthorsstatethatadeepvenousobstruc-
tion or atresia can lead to swelling and limb hypertrophy
[30]. Others state that the disease symptoms are caused by
a change in the angiopoietin-2 antagonist, which determines
the maintenance of small arteriovenous communications
in the limbs [34]. However, further experts argue that the
hypertrophy observed in soft tissues is a primary occurrence
that occurs independently of fistulas [35].
Klippel-Trenaunay-Weber syndrome is characterized
b yt h ep r e s e n c eo fc a p i l l a r ym a l f o r m a t i o n sa s s o c i a t e d
with venous malformations or varicose veins (Figure 3)
a n dw i t hb o n eo rt i s s u eh y p e r t r o p h y ;ad i a g n o s i so ft h i s
syndrome is based on the presence of at least two of these
three categories [29, 36]. 63% of diagnosed patients present4 Radiology Research and Practice
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Figure 3: A 60-year-old man with Klippel-Trenaunay-Weber syn-
drome presenting asymmetric growth of the lower limbs. CT of
the chest showed increased soft tissue as well as extensive vascu-
lar malformations in the left hemithorax wall with intermingled
phleboliths, causing multiple lytic lesions with enlargement in the
ipsilateralribs(a).CToftheabdomenshowedathick-walledrectum
intermingled with phleboliths, denoting varicose veins (b).
all three symptoms [35]. The most common manifestation,
present in 98% of patients, is capillary malformation, which
is represented by cutaneous hemangiomas or a port-wine
stain [29, 36]. These lesions usually affect the hypertrophied
limb, and when they occur in the trunk region, they rarely
cross the midline [29, 37–39]. Varicose veins are also
present in most patients with Klippel-Trenaunay-Weber
syndrome, and they are more evident during adolescence
and affect both the superficial and deep venous systems
[26, 29]. The varicose veins may remain stable or progress,
causing pain, lymphedema, thrombophlebitis, and ulcers
[30]. Hypertrophy, usually resulting from venous ectasia,
is always secondary to issues involving bone, soft tissue,
or both, which distinguishes this syndrome from Proteus
syndrome, in which bone and tissue overgrowth can occur
independently of vascular malformations [23, 30, 35, 40].
Other features also differentiate these two syndromes.
Klippel-Trenaunay-Weber syndrome is bilateral and less fre-
quently involves the upper limbs [23]. Some authors believe
that in Proteus syndrome, the limb overgrowth is usually
mild or absent at birth, while in Klippel-Trenaunay-Weber
syndrome it is present and severe at birth. Other authors
have stated that limb hypertrophy is the latest indicator of
Klippel-Trenaunay-Weber syndrome [30]. Bone overgrowth,
which is dysplastic, progressive, and irregular, is typical of
Proteus syndrome and not observed in Klippel-Trenaunay-
Weber syndrome; thus, its detection is an important tool in
differentiating between the diseases [23].
4. Madelung’s Disease
Madelung’s disease is also known as multiple symmetric
lipomatosis, benign symmetric lipomatosis, or Launois-
Bensaude adenolipomatosis. It is a rare condition that is
possibly related to alcohol consumption and leads to den-
ervation and subsequent adipocyte hypertrophy [41, 42].
Alcohol appears to play a role in the adipocyte hyperplasia
process in genetically susceptible individuals through the
prolipogenesis and antilipolytic effects [43]. However, other
s t u d i e sh a v ea l s os u g g e s t e dt h ep r e s e n c eo fm i t o c h o n d r i a l
inheritance through mutation of the maternal gene [44,
45]. Madelung’s disease is most common in adult males of
Mediterranean descent [46], with an estimated incidence of
1:25,000 in Italy [47].
It is manifested by the painless deposition of multiple
nonencapsulated masses of fatty tissue, which are symmet-
rically distributed in the cervical and upper thoracic regions
overaperiodofmonthstoyears.Theface,hands,andfeetare
usually unaffected. A Madelung’s disease diagnosis is based
on an ectoscopy as well as additional tests that rule out the
skin, vascular, and bone changes present in other diseases
[48]. This disease often leads to aesthetic complaints, but it is
rarely associated with complicationssuch asdyspnea (caused
by upper airway compression) or dysphonia (caused by an
involvement of the recurrent laryngeal nerve). Madelung’s
disease is classified as type I when lipomatous masses are
observed in the parotid, cervical, suprascapular, or deltoid
regions and classified as type II when the lipomatosis is
diffuse, resembling simple obesity [48].
Computed tomography (CT) is important for a
Madelung’s diagnosis because it can identify the key
symptoms, such as lipomatosis in the characteristic regions
(Figure 4), the calcification of lipomas, tracheal narrowing,
a n dv e n o u ss t a s i si nt h ec h e s tw a l l ,w h i l ec o n fi r m i n gt h e
absence of masses in other sites [46]. When performing a
differential diagnosis, diseases in addition to other over-
growth syndromes must be considered. When there are
similar cases in the family, familial lipomatosis is an option,
and Dercum’s disease (adiposis dolorosa) is a possibility if
the fat accumulation is accompanied by pain [23].
5. Neurofibromatosis Type I
Neurofibromatosis type I, also known as von Reckling-
hausen’s disease, was first described in 1882 by Friedrich
Daniel von Recklinghausen. Neurofibromatosis type I is the
most common type of phakomatosis or neurocutaneous
syndrome,occurringinoneoutofevery2000livebirthswith
no predilection for gender or race [49, 50]. It is an autosomal
dominant disorder caused by heterozygous mutations of the
NF-1 gene, located at chromosome 17q11.2 [51]. The NF1 gene
encodes a large cytoplasmic protein called neurofibromin,
which is a major negative regulator of Ras protooncogene, a
key protein in a major signal transduction pathway [50, 52].
In half of the cases, however, this disease occurs sporadically
via spontaneous mutations that cause abnormal growth in
nervous and fibrous tissues [49, 50].Radiology Research and Practice 5
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Figure 4: A 53-year-old man with Madelung’s disease presenting a
progressive painless increase of the cervical region. CT of the neck
and chest showed fat deposition occurring predominantly in the
posterior subcutaneous region of the neck (a) and in the supraclav-
icular and upper regions of the chest (b).
Clinical symptoms are usually observed in childhood,
though in approximately 10% of cases they occur later in life
andareatypical[48,53].NeurofibromatosistypeIcanexhibit
different clinical manifestations, which makes a diagnosis
more difficult. Generally, the disease affects the skin, nervous
system, bones, and endocrine glands by causing benign
tumors [49]. The diagnostic criteria for this disease were
d e v e l o p e di n1 9 8 7a n dr e d e fi n e di n1 9 9 7[ 50], and they are
based on the presence of two or more of the following find-
ings: a first-degree relative who has neurofibromatosis type
I, “caf´ e-au-lait” spots, neurofibromas, freckles in the axillary
or inguinal regions, optic gliomas, iris hamartomas, and
distinctive bone lesions.
The “caf´ e-au-lait” spots are present in approximately 95%
of diseased patients and are usually congenital; they occur in
different sizes and are distributed throughout the body sur-
face[50,54].Amongthemostfrequentskeletalabnormalities
observed in neurofibromatosis type I are scoliosis (Figure 5),
kyphosis, growth disorders, pseudarthrosis of long bones,
and sphenoid wing dysplasia [55]. Over time, patients with
neurofibromatosistypeImayexperienceabnormalitiesofthe
skeleton (thinning or overgrowth of the bones in the arms or
lower leg) [50, 55].
Figure 5: A 53-year-old man with neurofibromatosis type I. A
morphostructural abnormality in the spine is characterized by
significant dorsolumbar scoliosis with right convexity, as observed
in his CT scan (coronal section).
(a)
(b)
Figure 6: A 34-year-old woman with neurofibromatosis type I.
Axial CT show plexiform neurofibromas of lumbar and sacral nerve
roots.
Neurofibromas are the tumors of the peripheral nervous
system typically observed in this disease, particularly plexi-
form neurofibromas [49], which are derived from Schwann
cells and fibroblasts. Approximately 30% of patients with a
single neurofibroma will develop neurofibromatosis type I,
and virtually all patients with multiple neurofibromas, espe-
cially of the plexiform type (Figure 6), have the disease [49].6 Radiology Research and Practice
Iris hamartomas (Lisch nodules) are bilateral and asymp-
tomatic hamartomatous lesions on the surface of the iris.
M u l t i p l eh a m a r t o m a sa r eu n i q u et on e u r o fi b r o m a t o s i st y p e
I.
Several of the diagnostic criteria are confirmed by radi-
ological examinations. Tomographic findings depend on the
histological features of the tumorsand may exhibit soft tissue
density. More commonly (in 73% of cases) there is low atten-
uation due to cystic degeneration, confluent areas of hypo-
cellularity, or lipid abundance [49]. Neurofibromatosis is dis-
tinguished by its typical symptoms including neurofibromas,
Lisch nodules, axillary freckles, and “caf´ e-au-lait” spots,
which are absent in other overgrowth syndromes [23].
6. Conclusion
Overgrowth syndromes are characterized by diffuse or local-
ized tissue proliferation and they may originate in a dysfunc-
tional receptor tyrosine kinase (RTK)/PI3K/AKT pathway.
Thesesyndromesrepresentaheterogeneousgroupofdiseases
with manifestations that often overlap each other, requiring
the use of preestablished diagnostic criteria in most cases.
In this review, four overgrowth syndromes were charac-
terized according to their primary clinical and radiological
features. Identifying these features is important for mak-
ing the correct diagnosis and to appropriately monitor the
patient’s health because no specific genetic tests for these
syndromes are available.
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